Search clinical trials for: UGN-102

Total 5428 results

PhotonMD, Inc

Completed

Modulated Light Therapy in Participants With Pattern Hair Loss

Androgenetic Alopecia

Australia
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
Neurogene Inc.

Recruiting

Gene Therapy Study for Children With CLN5 Batten Disease (CLN5-200)

Neuronal Ceroid Lipofuscinosis CLN5

United States, United Kingdom
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
UroGen Pharma Ltd.

Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)

Carcinoma | Transitional Cell Carcinoma | Transitional Cell Cancer of the Renal Pelvis and Ureter

Israel, United States
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
Imperial College London
European Commission

Withdrawn

Modelling the Interaction Between Synthetic Model Immunogens and the Induced B and T Cell Repertoires. (MOSAIC)

Virus Diseases

United Kingdom
Transwell Biotech Co., Ltd.

Completed

TWB-103 for Treating Lower Limb Ulcers on Patients With DM

Diabetic Foot Ulcer

Taiwan
University of Oxford

Completed

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

Tuberculosis

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Kowa Research Institute, Inc.

Completed

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

Dyslipidemia

United States
Ludwig Boltzmann Gesellschaft

Recruiting

Extracorporal Shock Wave Treatment to Improve Nerve Regeneration

Peripheral Nerve Injury

Austria
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

Colorectal Cancer

Japan
Nektar Therapeutics

Completed

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Malignant Solid Tumor

United States, Belgium
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
Zafgen, Inc.

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Obesity | Prader-Willi Syndrome | Over-weight

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (GenePHIT)

Congestive Heart Failure

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

United Kingdom, France, Australia, Thailand, Portugal, Pakistan, Czechia, Greece
Nektar Therapeutics

Completed

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

United States
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Neothetics, Inc

Completed

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Weight

United States
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
Santen Inc.

Completed

Study Assessing Double-masked Uveitis Treatment (SAKURA)

Uveitis; Posterior, Disorder

United States, France, Italy, Poland, United Kingdom, Germany, Spain, Austria, Colombia, Israel, India, Turkey, Japan, Peru, Argentina, Brazil, Chile
Taipei Medical University

Completed

Health Evaluation of Mushrooms withVitamin D2

Healthy

Taiwan
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Allergan

Completed

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Duke University
National Institute on Drug Abuse (NIDA)

Recruiting

Low Nicotine Cigarettes, Smoking, and Chronic Pain (VLNCPain)

Chronic Pain | Smoking, Cigarette

United States
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Healthy Volunteers

Finland
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
Allergan

Completed

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Erythema | Rosacea

United States
CinDome Pharma, Inc.

Completed

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Gastroparesis

United States
University of Washington
Alaska Native Tribal Health Consortium

Completed

Improving Firearm Storage in Alaska Native Villages

Wounds and Injuries | Suicide, Attempted | Suicide

United States
Conceptra Biosciences, LLC

Recruiting

CCT-102 vs. Expectant Management in Delayed Pregnancy Loss (MERMAID)

Early Pregnancy Loss, Delayed Pregnancy Loss

United States
Allergan

Completed

AGN-199201 for the Treatment of Erythema With Rosacea

Erythema | Rosacea

United States
Allergan

Completed

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

Healthy Volunteers

United States
Tranzyme, Inc.

Completed

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Gastroparesis

United States, Belgium, Denmark, Finland, Germany, Norway, Poland, Sweden
Allergan

Completed

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Presbyopia

United States
Allergan

Completed

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Urinary Bladder, Overactive

France, United States, Netherlands
Taro Pharmaceuticals USA

Completed

An Open-Label Study to Assess Safety

Plaque Psoriasis

United States
AEterna Zentaris
AGO Study Group

Completed

Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors

Ovarian Cancer | Endometrial Cancer

Bulgaria, Germany
Allergan

Terminated

A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

United States, Austria, Poland, Germany
Allergan

Completed

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Erythema | Rosacea

United States
Allergan

Completed

AGN-229666 for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

Japan
Allergan

Completed

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United States, Czech Republic, Germany
AmtixBio Co., Ltd.

Not yet recruiting

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Onychomycosis

New Zealand
Bayer

Completed

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

Sunscreen Agents

United States

Search clinical trials for: UGN-102

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations